Cargando…
Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17–36
The currently available nonavalent human papillomavirus (HPV) vaccine exploits the highly antigenic L1 major capsid protein to promote high-titer neutralizing antibodies, but is limited to the HPV types included in the vaccine since the responses are highly type-specific. The limited cross-protectio...
Autores principales: | Bywaters, Stephanie M., Brendle, Sarah A., Tossi, Kerstin P., Biryukov, Jennifer, Meyers, Craig, Christensen, Neil D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707543/ https://www.ncbi.nlm.nih.gov/pubmed/29125554 http://dx.doi.org/10.3390/v9110336 |
Ejemplares similares
-
Cleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection
por: Cruz, Linda, et al.
Publicado: (2015) -
Mutations in HPV18 E1^E4 Impact Virus Capsid Assembly, Infectivity Competence, and Maturation
por: Biryukov, Jennifer, et al.
Publicado: (2017) -
High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility
por: Goetschius, Daniel J., et al.
Publicado: (2021) -
Roles for Human Papillomavirus Type 16 L1 Cysteine Residues 161, 229, and 379 in Genome Encapsidation and Capsid Stability
por: Ryndock, Eric J., et al.
Publicado: (2014) -
Antibody escape by polyomavirus capsid mutation facilitates neurovirulence
por: Lauver, Matthew D, et al.
Publicado: (2020)